David A. Dodd Purchases 10,000 Shares of GeoVax Labs, Inc. (NASDAQ:GOVX) Stock

GeoVax Labs, Inc. (NASDAQ:GOVX) CEO David A. Dodd acquired 10,000 shares of the stock in a transaction dated Tuesday, April 1st. The shares were purchased at an average price of $1.08 per share, for a total transaction of $10,800.00. Following the completion of the transaction, the chief executive officer now owns 36,661 shares of the company’s stock, valued at $39,593.88. This trade represents a 37.51 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

GeoVax Labs Price Performance

Shares of NASDAQ:GOVX traded up $0.02 during mid-day trading on Tuesday, hitting $1.08. The company had a trading volume of 329,440 shares, compared to its average volume of 617,522. The company has a market capitalization of $10.19 million, a PE ratio of -0.19 and a beta of 3.06. GeoVax Labs, Inc. has a one year low of $1.03 and a one year high of $11.18. The firm has a fifty day moving average price of $1.64 and a 200 day moving average price of $2.11.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.49. The firm had revenue of $3.00 million for the quarter, compared to the consensus estimate of $2.38 million. Research analysts expect that GeoVax Labs, Inc. will post -4.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GeoVax Labs

Several institutional investors have recently bought and sold shares of GOVX. Virtu Financial LLC bought a new position in GeoVax Labs in the third quarter worth about $97,000. Geode Capital Management LLC lifted its stake in GeoVax Labs by 59.0% during the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after acquiring an additional 33,440 shares during the period. Northern Trust Corp purchased a new position in shares of GeoVax Labs in the 4th quarter worth $29,000. Finally, Citadel Advisors LLC bought a new position in shares of GeoVax Labs in the 4th quarter worth approximately $104,000. 6.09% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, D. Boral Capital reaffirmed a “buy” rating and issued a $18.00 price target on shares of GeoVax Labs in a report on Friday. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $14.20.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.